Medpace Holdings Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Medpace Holdings Inc trades at $532.94 (market cap $15.08B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.49. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| MEDP | USIG | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | Fixed Income |
52-Week High | $620.59 | $52.69 |
52-Week Low | $308.88 | $50.50 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
USIG (iShares Broad USD Investment Grade Corporate Bond ETF) trades at $50.605, down 0.27% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 51.10. Recent corporate actions include dividend payments of $0.20-$0.21 per share. Short interest surged 63.4% in April 2026, indicating growing bearish sentiment among traders.
The ETF faces headwinds from rising short interest and bearish technical positioning. Investment grade corporate bond exposure provides stability but current market sentiment suggests caution. The dividend yield remains modest while technical indicators point to potential near-term pressure on the share price.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →